1. Ahmann DL, Bisel HF, Hahn RG (1974) Phase II clinical trial of ifosfamide (NSC-109724) in patients with advanced breast cancer. Cancer Chemother Rep 58:861?865
2. Brock N (1980) The development of mesnum for the inhibition of uro-toxic side effects of cyclophosphamide, ifosfamide and other oxazaphosphorine cytostatics. Recent Results Cancer Res 74:270?728
3. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979a) Acrolein, the causative factor of urotoxic side effects of cyclophosphamine, ifosfamide, trofosfamide and sufosfamide. Arzneim Forsch 29:659?661
4. Brock N, Stekar J, Pohl J (1979b) Antidot gegen urotoxische Wirkugen der Oxazaphosphorin-Derivate Cyclophosphamid, Ifosfamid und Trofosfamid. Naturwissenschaften 66:60?61
5. Bryant BM, Jarman M, Ford HT, Smith IE (1980) Prvention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulfonate sodium (Mesnum) in patients with advanced carcinoma. Lancet II:257?259